Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Jetstar to Charge for Overhead Cabin Bags From February 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
LAWRENCEVILLE, N.J., March 12, 2018 -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018 at 3:30 p.m. local time. The conference will be held March 15-17, 2018 at The InterContinental Hotel Hangzhou, China.
- The Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 9:10 a.m. EDT. The conference will be held March 20-21, 2018 at The Westin New York Grand Central in New York City.
A live webcast of Celsion’s presentation at the Oppenheimer conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at www.celsion.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation or until June 19, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: www.celsion.com. (CLSN-FIN)
ThermoDox® is a registered trademark of Celsion Corporation.
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
